FHTX Q2 2023 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

FHTXFoghorn Therapeutics Inc.

$330M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+24.7% YoY

Gross Profit

-$24M-422.4% margin

Operating Income

-$32M-572.4% margin

Net Income

-$29M-526.6% margin

EPS (Diluted)

$-0.70

QoQ Revenue Growth

+5.5%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$340M

Total Liabilities

$389M

Stockholders' Equity

-$49M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+24.7%
Gross Profit	-$24M	-$21M	-10.1%
Operating Income	-$32M	-$29M	-9.8%
Net Income	-$29M	-$27M	-8.0%